Written by Robert Huebner, Ph.D., “Leveraging modernization of the US influenza vaccine manufacturing base to make better vaccines: a work in progress” was recently published in Vaccine Insights.
Dr. Huebner was asked by the journal to write a Viewpoint article on vaccine manufacturing.
“My piece focuses on how we can leverage our recent vaccine manufacturing advances to develop and produce better influenza vaccines—based on principles for improved influenza vaccines that a group I was part of developed at BARDA,” he says.
Dr. Huebner is an experienced biotechnology program manager with more than 30 years of research and development experience with viral and microbiological pathogens and expertise in the biologics industry, pandemic preparedness, group management, and program management. Throughout his career, he has worked for a variety of organizations, large pharma companies, government agencies, and a contract research organization, holding positions of increasing responsibility.
At LBG, Dr. Huebner supports both commercial and U.S. Government-funded programs as a subject matter expert on biopharmaceutical advanced development, analytical testing, strategic planning, and program management. He also leads the vaccine practice and is part of the team that helps clients win and secure non-dilutive U.S. Government funding.
Prior to joining LBG, Dr. Huebner worked at BARDA, where he held several positions, including Deputy Director and Acting Director of the Influenza Division and Chief of Universal Influenza Vaccine Development.
Vaccine Insights is a new peer-reviewed, open-access journal that focuses on the development and manufacture of vaccines.
To learn more, visit insights.bio/vaccine-insights.
